


## OPPORTUNITY & MISSION

- ✓ **IMPROVING PATIENT OUTCOMES** – faster recovery; reducing morbidity, risk of amputation and mortality
- ✓ **REDUCING THE BURDEN FOR PROVIDERS** - reducing failures, repeated procedures affecting financial operation and quality metrics
- ✓ **REDUCING OVERALL HEALTHCARE COSTS** – shifting infection treatment to less invasive approaches, reducing the practice of removing metal implant components


## NON-TARGETED ANTIBIOTIC DOSING VS TARGETED ANTIBIOTIC DOSING

**Current administration methods** are sub-therapeutic, unable to achieve MBEC Minimum Biofilm Eradication Concentration (red dashed line)



**Persistent biofilm is the primary reason for current infection treatment failure**

**Relevant clinical research** with cyclic, local, super-therapeutic concentrations proves superior outcomes without patient injury<sup>10</sup>



**US Economic Impact for treating Periprosthetic Joint Infection is \$1.6B (2020) and growing<sup>14</sup>**

**For Joints, by 2024:**  
 >1.4M / yr Total US Primary Joints (hips & knees);  
 >8.1M Americans with Total Joint Implants;  
 Est: >50k / yr US Total Joint Infections

**For Spine:**  
 1.62M / yr US Instrumented Spinal Fusions<sup>12</sup>  
 Est: 30k / yr US Spinal infection<sup>13</sup>  
 Mortality ~ 20%<sup>13</sup>

Better treatment can expand less invasive methods with **Implant Retention**;

A potential Savings of >\$90,000 / patient, over current 2-stage procedure that removes the entire implant<sup>11</sup>

## LOCAL ANTIBIOTICS VIA SIMPLE, LOW COST, PROGRAMMABLE DELIVERY



**Implant:** reservoir/pump - without hazardous content, without batteries, motors or electronics  
**External Controller:** proprietary "coupling" to the implanted pump through the skin

## LOWER TREATMENT COST, REDUCED MORBIDITY, REDUCE MORTALITY

Come join us at ForCast Ortho where we are advancing our novel implantable drug delivery platform that can achieve targeted delivery of programmable dosing regimens at a low cost. Our platform has broad applications with our initial focus on treating PJI patients with existing/known antibiotics, achieving therapeutic concentrations that drive improved patient outcomes. We have a strong team, demonstrated feasibility, issued patents and a clear regulatory strategy.